Company intelligence / Profile preview

Tricentis

Austin, Texas, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Commercial

Overview

Tricentis provides AI-powered automated software testing and digital validation platforms that help healthcare and life sciences organizations modernize computer system validation, ensure regulatory compliance with standards like FDA 21 CFR Part 11, accelerate innovation cycles, reduce manual errors and costs by up to ~40%, and mitigate risk in regulated environments. Their acquisition of Tx3 Services expanded their capabilities specifically for the life sciences sector. They do not develop drugs or medical devices themselves but enable faster compliant software delivery for those who do.

Industry: Biomedical IT and Biomedical Data Platforms

Partnerships

Partners with various technology integrators and consulting firms to implement its platforms globally; specific pharma/biotech partnerships are not listed but serves major healthcare/life science clients.

Beyond the preview

Go deeper on Tricentis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tricentis.

Explore the full profile